A randomised, placebo-controlled, double blind phase III study of the efficacy and safety of recombinant human C1 inhibitor for the treatment of acute attacks in patients with hereditary angioedema

Marco Cicardi; Roberto Perricone; Mauro Cancian; Vincenzo Montinaro; Enrico Cillari; Teresa Gonzalez-Quevedo; Sergio Neri; Massimo Triggiani; Hilary Longhurst; Cornelis Hack; Rene Verdonk; Bruno Giannetti; Jan Nuijens

doi:10.1016/j.molimm.2008.08.069

A randomised, placebo-controlled, double blind phase III study of the efficacy and safety of recombinant human C1 inhibitor for the treatment of acute attacks in patients with hereditary angioedema

Molecular Immunology ◽

10.1016/j.molimm.2008.08.069 ◽

2008 ◽

Vol 45 (16) ◽

pp. 4118-4119 ◽

Cited By ~ 1

Author(s):

Marco Cicardi ◽

Roberto Perricone ◽

Mauro Cancian ◽

Vincenzo Montinaro ◽

Enrico Cillari ◽

...

Keyword(s):

Hereditary Angioedema ◽

Phase Iii ◽

Efficacy And Safety ◽

C1 Inhibitor ◽

Double Blind ◽

Phase Iii Study ◽

Acute Attacks

Download Full-text

A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC

Case Medical Research ◽

10.31525/ct1-nct04033354 ◽

2019 ◽

Author(s):

Keyword(s):

Stage Iiib ◽

Phase Iii ◽

Line Treatment ◽

Efficacy And Safety ◽

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text

A Randomized, Double-blind, Placebo‑Controlled Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy (Carboplatin- Etoposide) in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Case Medical Research ◽

10.31525/ct1-nct04063163 ◽

2019 ◽

Author(s):

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study ◽

Extensive Stage

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718340215.793493941 ◽

2014 ◽

Author(s):

Kamran Ghoreschi ◽

Sebastian Volc

Keyword(s):

Monoclonal Antibody ◽

Plaque Psoriasis ◽

Phase Iii ◽

Efficacy And Safety ◽

Chronic Plaque Psoriasis ◽

Double Blind ◽

Phase Iii Study

Download Full-text

Comparison of the Efficacy and Safety Profiles of a Pelubi Sustained Release Tab Versus a Pelubi Tab in Patients with Chronic Back Pain: A Randomized, Double-Blind, Multi-Institution Phase III Study

Journal of Korean Society of Spine Surgery ◽

10.4184/jkss.2016.23.2.92 ◽

2016 ◽

Vol 23 (2) ◽

pp. 84

Author(s):

Ki Taek Kim ◽

Tae Kyun Kim ◽

Ji Woong Choi ◽

Jae Sung Ahn ◽

Young Do Koh ◽

...

Keyword(s):

Back Pain ◽

Sustained Release ◽

Chronic Back Pain ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Study

Download Full-text

Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: Results of a double-blind, randomized, placebo-controlled, phase-III study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2014.01.897 ◽

2014 ◽

Vol 71 (3) ◽

pp. 484-492 ◽

Cited By ~ 49

Author(s):

D.S. Krupashankar ◽

Sunil Dogra ◽

Mahendra Kura ◽

Abir Saraswat ◽

Leelavathy Budamakuntla ◽

...

Keyword(s):

Monoclonal Antibody ◽

Plaque Psoriasis ◽

Phase Iii ◽

Efficacy And Safety ◽

Chronic Plaque Psoriasis ◽

Double Blind ◽

Phase Iii Study

Download Full-text

Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study

Advances in Therapy ◽

10.1007/s12325-021-01899-0 ◽

2021 ◽

Author(s):

Lin Cai ◽

Linfeng Li ◽

Hao Cheng ◽

Yangfeng Ding ◽

Zhenshu Biao ◽

...

Keyword(s):

Plaque Psoriasis ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Severe Plaque Psoriasis ◽

Phase Iii Study

Download Full-text

Correction: Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non–small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-19-1098 ◽

2019 ◽

Vol 25 (10) ◽

pp. 3193-3193

Author(s):

Nicholas Thatcher ◽

Jerome H. Goldschmidt ◽

Michael Thomas ◽

Michael Schenker ◽

Zhiying Pan ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Double Blind ◽

Phase Iii Study

Download Full-text

Efficacy and safety of BCD-021, bevacizumab biosimilar candidate, compared to Avastin: Results of international multicenter randomized double blind phase III study in patients with advanced non-squamous NSCLC.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.8057 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 8057-8057 ◽

Cited By ~ 6

Author(s):

Olga Filon ◽

Sergey Orlov ◽

Olga Burdaeva ◽

Mikhail V. Kopp ◽

Bogdan Kotiv ◽

...

Keyword(s):

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Study ◽

International Multicenter

Download Full-text

Comparison of the Efficacy and Safety of Atorvastatin 40 mg/ω-3 fatty acids 4 g Fixed-Dose Combination and Atorvastatin 40 mg Monotherapy in Hypertriglyceridemic Patients Who Poorly Respond to Atorvastatin 40 mg Monotherapy: An 8-Week, Multicenter, Randomized, Double-Blind Phase III Study

Clinical Therapeutics ◽

10.1016/j.clinthera.2021.07.001 ◽

2021 ◽

Author(s):

Jong Shin Woo ◽

Soon Jun Hong ◽

Dong Hoon Cha ◽

Kee Sik Kim ◽

Moo Hyun Kim ◽

...

Keyword(s):

Fatty Acids ◽

Fixed Dose Combination ◽

Phase Iii ◽

Fixed Dose ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Study ◽

Dose Combination

Download Full-text

Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study

The Lancet ◽

10.1016/s0140-6736(08)60524-3 ◽

2008 ◽

Vol 371 (9619) ◽

pp. 1181-1189 ◽

Cited By ~ 272

Author(s):

Alexandre C Linhares ◽

F Raúl Velázquez ◽

Irene Pérez-Schael ◽

Xavier Sáez-Llorens ◽

Hector Abate ◽

...

Keyword(s):

Latin American ◽

Phase Iii ◽

Rotavirus Vaccine ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Rotavirus Gastroenteritis ◽

Human Rotavirus ◽

Phase Iii Study

Download Full-text